Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will present a corporate overview and participate in a Q&A discussion at the MST Access Rare Diseases, Rich Returns Forum on Thursday, ...
Category: Investor Announcement
– ATH434 now being evaluated in early and more advanced Multiple System Atrophy – – New trial expected to generate data before ongoing Phase 2 trial – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 30 May 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will present at the SHARE Series Monday Management Update on Monday, May 22, 2023, at 11:00 am ET. This event is set ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first participant in Australia has been treated in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder. “The dosing ...
Highlights: MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 27 April 2023. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st March 2023 (Q3 ...
– Wearable sensor parameters correlate strongly with clinical scales of motor impairment – Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that promising wearable sensor data from the Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first participant has been dosed in the United Kingdom in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA). “MSA is a rare and highly debilitating ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first participant has been dosed in the U.S. in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder. “The ...
– Composition of matter patent from USPTO covers more than 100 novel compounds targeting neurodegenerative diseases including Alzheimer’s – – Newly patented compounds and legacy asset PBT2 licensed to Professor Colin Masters for evaluation in Alzheimer’s and related diseases – Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases is pleased to announce its participation in the ShareCafe Small Cap “Hidden Gems” Webinar, to be held Friday 10th of March 2023 from 12:30pm AEDT/ 9:30am AWST. Dr David Stamler – CEO will ...